PTC Therapeutics | PTCT - Debt


PTC Therapeutics reported $2.84B in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.3B 19M Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Cytokinetics USD 1.27B 18.17M Jun/2026
Daiichi Sankyo JPY 500.48B 200B Jun/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 26.25B 4.07B Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
TG Therapeutics USD 754.44M 884K Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026
Xencor USD 170.11M 5.06M Jun/2026